Αναζήτηση

σε πρόσθεσε στο Health

2026-01-27 09:57:12 -

How does the IL-17A inhibitor secukinumab (Cosentyx) change the rules of inflammation management?

In the field of immune-mediated inflammatory disease (IMID) treatment, the advent of biologic therapies has broken the limitations of traditional approaches and brought renewed hope for recovery to countless patients. As the world’s first fully human monoclonal antibody targeting interleukin-17A (IL-17A) to receive regulatory approval, secukinumab (Cosentyx) injection has demonstrated...

0 Σχόλια 0 Μοιράστηκε 167 Views 0 Προεπισκόπηση